Short answer: There are no publicly announced or disclosed programs to develop a biosimilar (or “biosimilar‑type” product) for nirsevimab.
---
Why that’s the case
| Factor | Impact on biosimilar development |
|--------|----------------------------------|
| Novel mechanism – Nirsevimab is a next‑generation RSV‑neutralizing monoclonal antibody that incorporates several design elements (e.g., Fc‑domain engineering for extended half‑life, engineered glycosylation, and a novel antigen‑binding scaffold). | The combination of these features creates a “non‑generic” product that is much harder to replicate. |
| Complex manufacturing – Large‑scale antibody production involves cell‑line development, fermentation, purification, and stringent quality controls that are tightly guarded trade secrets. | Any competitor would have to establish an entirely new cell‑line and production platform, a costly and time‑consuming endeavor. |
| Regulatory pathway – For a biosimilar to an antibody, the sponsor must demonstrate no clinically meaningful differences in safety, purity, potency, and efficacy. Because nirsevimab’s mechanism is unique and its clinical benefit (prophylaxis against RSV in infants) is tied to a very specific dosing regimen, the regulatory hurdle is high. | Sponsors usually start with antibodies that have been on the market longer and whose manufacturing processes are well understood (e.g., trastuzumab, rituximab). |
What the market looks like right now
* Sanofi/AstraZeneca – The original developers and current commercial holders. They are focusing on expanding the product’s indications and global rollout rather than licensing to other manufacturers.
* Potential entrants – Several large biotech firms (e.g., Amgen, Johnson & Johnson, Roche) and smaller antibody developers routinely search for “low‑hanging fruit” for biosimilars. However, none have publicly disclosed a nirsevimab‑related project in 2024‑2025.
* Patents and exclusivities – Nirsevimab’s key patents (covering its amino‑acid sequence, glycosylation pattern, and Fc‑engineered half‑life extension) are still active. These patents would block a straightforward biosimilar approach until they expire (likely after 2028‑2030).
How to spot a future biosimilar
* Regulatory filings – Watch the FDA’s “Biosimilars” database and the EMA’s “Biosimilars” portal. Any new application for a nirsevimab‑like product would be listed there.
* Clinical trial registries – Check ClinicalTrials.gov, EU Clinical Trials Register, and WHO’s ICTRP for new studies under “nirsevimab” or “RSV monoclonal antibody” that are labeled “biosimilar” or “intermediate biologic”.
* Patent landscape – Use patent search tools (e.g., Google Patents, Derwent) to see if any new patents are being filed that could indicate a company is working on a similar antibody platform.
---
Bottom line
As of the latest public data (mid‑2026), no company has announced a nirsevimab biosimilar program. The combination of a highly engineered antibody, robust patents, and the early stage of its commercialization makes a biosimilar launch unlikely in the short term. If you’re tracking a specific company’s pipeline, their corporate communications or investor presentations would be the best source for the most up‑to‑date information.